Promising Clinical Results and Strategic Developments Drive Buy Rating for Zai Lab
I'm PortAI, I can summarize articles.
Yigal Nochomovitz has issued a Buy rating for Zai Lab, citing promising Phase 1 trial results for zoci, an ADC targeting DLL3 in SCLC patients with untreated brain metastases, showing an 80% response rate. The initiation of a global study for extensive-stage SCLC aims for accelerated approval by 2027. Despite competitive concerns, a potential 162.2% upside in share price supports the positive outlook. Leerink Partners also reiterated a Buy rating with a $74.00 price target. Nochomovitz has a 7.6% average return and 42.74% success rate on recommended stocks.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments